000			nab a22 7a 4500
999			_c16914 _d16914
003			PC16914
005			20220620120251.0
008			220620b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia
245	0	0	_aDeep Response in Multiple Myeloma: A Critical Review. _h[revisión]
260			_bBioMed research international, _c2015
300			_a2015:832049.
500			_aFormato Vancouver: Fulciniti M, Munshi NC, Martínez López J. Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int. 2015;2015:832049.
501			_aPMID: 26783530 PMC4689894
504			_aContiene 55 referencias
520			_aNovel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients' survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factors in MM and should be included in a new definition of complete response (CR). Although further standardization is still required, MRD monitoring should be applied in prospective clinical trials as a sensitive tool to compare and evaluate the efficacy of different treatment strategies, particularly in the consolidation and maintenance settings, and implement individualized therapy-monitoring approaches. Here, we review current definition of deep response in MM, advantages and limitations of current MRD assessment assays, clinical evidences for MRD monitoring as a prognostic tool for therapeutic decisions in MM, and challenges to develop uniform criteria for MRD monitoring.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689894/ _yAcceso libre
942			_2ddc _cREV _n0